COMMUNIQUÉS West-GlobeNewswire

Origin Medical Announces Leadership Transition and Expands Executive Team Ahead of Commercial Launch
01/06/2026
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Origin Medical, a pioneer in AI-powered ultrasound workflow solutions that improve access and support clinicians in delivering prenatal care, today announced a [...]
EssilorLuxottica: Result of the payment of dividends in shares and record of the corresponding capital increase
01/06/2026
Result of the payment of dividends in shares and record of the corresponding capital increase Paris, France (June 1, 2026) – The Annual General Meeting of EssilorLuxottica has decided to grant to the shareholders the [...]
EssilorLuxottica: Résultat du paiement du dividende en actions et constatation de l’augmentation de capital correspondante
01/06/2026
Résultat du paiement du dividende en actions et constatation de l’augmentation de capital correspondante Paris, France (1 er juin 2026) – L’Assemblée générale annuelle d’EssilorLuxottica a décidé de donner aux [...]
Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026
01/06/2026
LB2102 demonstrated a manageable safety profile and encouraging clinical activity in solid tumors among heavily pretreated patients Responses observed at higher dose levels of LB2102 with an ORR of 28.6% and a DCR of 78 [...]
Zorronet Brings Autonomous C5ISR to Hardened Sites Without Public Cloud Dependence
01/06/2026
The company introduces an expanded on-premise and hybrid C5ISR suite that enables local AI processing, command automation, and response coordination for defense, security, and critical infrastructure NETANYA, Israel, [...]
Introducing Evosep Proteomics to Standardize and Scale Proteomics for Research and Drug Development
01/06/2026
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Evosep announces the launch of Evosep Proteomics, an ecosystem designed to standardize and scale LC-MS–based proteomics for research and pharmaceutical drug development. [...]
Ardena appoints Ariane de Ganck as Chief Scientific Officer
01/06/2026
Ghent, Belgium, June 1, 2026 - Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and complex therapies, today announced the appointment of Ariane de Ganck, PhD, as Chief [...]
Mapi Pharma to Participate in the ASCO Annual Meeting and ADA 2026 Scientific Sessions
01/06/2026
Company is seeking partnerships for the most advanced long-acting depot injections in its pipeline, including Anastrozole Depot and Semaglutide Depot NESS ZIONA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd [...]
Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches
01/06/2026
Early results from solid tumor model support additional studies in pancreatic and colorectal cancer models; full dataset planned for presentation later in 2026 SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics [...]
Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting
01/06/2026
- Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, minimally invasive intratumoral treatment that fits naturally into the patient journey - - Pooled analysis of three prospective Phase [...]
Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus
01/06/2026
Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markers Demonstrated superior diagnostic accuracy compared with conventional testing, supporting earlier, more definitive [...]
AIM ImmunoTech Completes Phase 2 DURIPANC Enrollment Milestone Ahead of Schedule, Advancing Ampligen Toward Critical Pancreatic Cancer Clinical Milestones
01/06/2026
Final Subject Meets Enrollment Criteria and is Scheduled for Mid-June Treatment, More Than One Month Ahead of Original Target OCALA, Fla., June 01, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM [...]
LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors
01/06/2026
Bringing More Than Three Decades of Energy Investment Experience, Mr. Porter Has Helped Build a Global Power Infrastructure Portfolio, Strengthening LIXTE’s Strategic Expansion into AI Energy Infrastructure BOCA RATON, [...]
Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
01/06/2026
ISELIN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, [...]
Wave Life Sciences to Present at Upcoming Investor Conferences
01/06/2026
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, [...]
Oak Hill Bio Raises $32.5 Million Series A Financing to Advance Antisense Oligonucleotide Therapy Rugonersen to Phase 3 Study in Angelman Syndrome
01/06/2026
Series A financing co-led by Balyasny Asset Management, venBio, and Janus Henderson Investors Rugonersen, a potentially best-in-class antisense oligonucleotide (ASO) therapy for Angelman syndrome, is expected to enter a [...]
Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients
01/06/2026
The expanded access program (EAP) is available to eligible patients with erythropoietic protoporphyria (EPP) and provides access to bitopertin prior to regulatory decision Bitopertin, an oral glycine transporter 1 ( [...]
IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026
01/06/2026
Repeat dosing of DeltEx TM Drug Resistant Immunotherapy (DRI) had a median progression-free survival (mPFS) of 13.0 months and median overall survival (mOS) exceeding 19.5 months (not yet reached). Results demonstrate [...]
PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀
01/06/2026
If approved, D-PLEX 100 would address a critical unmet medical need in the prevention of surgical site infections PDUFA target action date currently planned for the first quarter of 2027 PETACH TIKVA, Israel, June 01, [...]

Pages